[Mutations of HBV polymerase gene sequence in lamivudine-resistant chronic hepatitis B patients].
OBJECTIVE
To explore the characteristics of mutation in HBV polymerase (P) gene reverse transcriptase region (RT region) in lamivudine-resistant chronic hepatitis B (CHB) patients.


METHODS
This study involved 115 CHB patients who developed clinical resistance to lamivudine. Direct sequencing of the PCR products was used to detect lamivudine genotypic resistance.


RESULTS
Lamivudine resistant mutation was detected in 103 patients, and the major mutations included rtL180M+rtM204V and rtM204I, accounting for 58.3% and 22.3%, respectively. Other resistant substitutions included rtL80V/I, rtT184S, and rtA200V, and combined mutation of triple resistant substitutions was detected in HBV RT region of 5 patients by direct sequencing.


CONCLUSIONS
For lamivudine-treated patients, combined mutation at the sites other than rtL180 and rtM204 in HBV P gene should also be detected for drug resistance evaluation.
Wang
Cheng
C
Department of Infectious Disease, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. doc_chengwang@126.com
Sun
Jian
J
Chen
Jin-jun
JJ
Wang
Zhan-hui
ZH
Hou
Jin-lin
JL
D019380:Anti-HIV Agents / Q000627:therapeutic use; D024882:Drug Resistance, Viral / Q000235:genetics*; D015684:Gene Products, pol / Q000235:genetics*; D006515:Hepatitis B virus / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D009154:Mutation
D019380:Anti-HIV Agents; D015684:Gene Products, pol; C066027:P protein, Hepatitis B virus; D019259:Lamivudine